A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

Study Overview

• Status: Completed
• Conditions: Severe Hypertriglyceridemia; Mixed Dyslipidaemia
• Intervention / Treatment: Drug: Gemcabene; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 91
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Chicoutimi, Quebec, Canada, G7H 7K9
      • Ecogene-21
• United States
  • Alabama
    • Fort Payne, Alabama, United States, 35967
      • Appalachian Research Associates
  • Arizona
    • Tucson, Arizona, United States, 85710
      • Del Sol Research Mangagement, LLC
  • California
    • Beverly Hills, California, United States, 90211
      • Westside Medical Associates of Los Angeles
    • Canoga Park, California, United States, 91303
      • HOPE Clinical Research
    • Garden Grove, California, United States, 92844
      • SC Clinical Research
    • Huntington Park, California, United States, 90255
      • National Research Institute
    • Los Angeles, California, United States, 90057
      • National Research Institute
    • San Diego, California, United States, 92117
      • Paradigm Clinical Research
  • Colorado
    • Wheat Ridge, Colorado, United States, 80033
      • Paradigm Research
  • Florida
    • Boca Raton, Florida, United States, 33434
      • Excel Medical Research
    • Bradenton, Florida, United States, 34201
      • Meridien Research
    • Hialeah, Florida, United States, 33012
      • Indago Research and Health Center
    • Hialeah, Florida, United States, 33012
      • Direct Helpers Research Center
    • Jacksonville, Florida, United States, 32216
      • Jacksonville Center for Clinical Research
    • Lauderdale Lakes, Florida, United States, 33319
      • Sunrise Medical Research
    • Miami, Florida, United States, 33015
      • San Marcus Research Clinic, Inc.
    • Miami, Florida, United States, 33165
      • MedCare Research
    • Miami, Florida, United States, 33125
      • Millenium Clinical Research, Inc.
    • Miami Lakes, Florida, United States, 33014
      • AR Developoment Solutions
    • West Palm Beach, Florida, United States, 33406
      • Soma Medical Research
  • Illinois
    • Evanston, Illinois, United States, 60201
      • Evanston Premier Clinical Research
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • Midwest Institute for Clinical Research, Inc.
  • Kansas
    • Junction City, Kansas, United States, 66441
      • Richard Lochamy, M.D.
    • Kansas City, Kansas, United States, 66160
      • University of Kansas Medical Center
  • Kentucky
    • Louisville, Kentucky, United States, 40213
      • L-MARC Research Center
  • Louisiana
    • Covington, Louisiana, United States, 70433
      • Clinical Trials Management, LLC
    • Metairie, Louisiana, United States, 70006
      • Clinical Trials Management, LLC
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland Medical Center
  • Michigan
    • Ann Arbor, Michigan, United States, 48105
      • University of Michigan Health Systems
  • Mississippi
    • Jackson, Mississippi, United States, 39202
      • Elite Clinical Research
  • Nevada
    • Las Vegas, Nevada, United States, 89121
      • Clinical Research of South Nevada
  • New York
    • Bronx, New York, United States, 10455
      • CHEAR Center, LLC
    • Bronx, New York, United States, 10468
      • Advantage Clinical Trials
  • North Carolina
    • Benson, North Carolina, United States, 27504
      • Eastern Carolina Medical Clinic
    • Farmville, North Carolina, United States, 27828
      • Physicians East, NA
    • Greenville, North Carolina, United States, 27834
      • Physicians East, NA
    • Morrisville, North Carolina, United States, 27560
      • Cary Medical Clinic
  • Ohio
    • Columbus, Ohio, United States, 43235
      • Optimed Research
    • Dayton, Ohio, United States, 45419
      • PriMED Clinical Research
  • Pennsylvania
    • Lansdale, Pennsylvania, United States, 19446
      • Green and Seidner Family Practice Associates
  • Rhode Island
    • Lincoln, Rhode Island, United States, 02865
      • BTC of Lincoln
  • South Carolina
    • Rock Hill, South Carolina, United States, 29732
      • Carolinas Research Partners, LLC
  • Texas
    • Houston, Texas, United States, 77091
      • Airline Complete Healthcare
    • Kerrville, Texas, United States, 78028
      • Sante Clinical Research
    • Lampasas, Texas, United States, 76550
      • FMC Science
    • Plano, Texas, United States, 75075
      • Clinical Investigations of Texas
    • San Antonio, Texas, United States, 78215
      • Sun Research Institute
  • Wisconsin
    • Kenosha, Wisconsin, United States, 53142
      • Clinical Investigation Specialists

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects who meet all of the following criteria will be eligible to participate in the study:

1. Provision of written and signed informed consent (by subject or legal guardian) prior to any study-specific procedure;

2. Male or female (neither pregnant or lactating) ≥18 years of age at time of consent;

   1. Women of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine dipstick on Study Day 1 prior to dosing in order to qualify for the study. Women who are surgically sterile or are clinically confirmed to be post-menopausal (i.e., documented amenorrhea for ≥ 1 year in the absence of other biological or physiological causes) are not considered to be of child-bearing potential;
   2. Women of child-bearing potential must agree to use acceptable methods of contraception throughout the duration of the study and for 30 days after the last dose of study drug. For this study, double-barrier contraception is required.
3. Currently on a self-reported, stable, low-fat, low-cholesterol diet in combination with stable statins with or without ezetimibe (10 mg QD) for at least 12 weeks prior to the Screening Visit;
4. Mean fasting TG value ≥ 500 mg/dL to < 1500 mg/dL (with the higher value no more than 50% greater than the lower value) from the S1 and S2 Visits (or alternatively S2 and S3);
5. Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator;
6. Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m²; and
7. Subjects with Type 2 diabetes who take anti-diabetes pharmacologic therapy must be on a stable a regimen for at least 3 months, with no planned changes in medications for the study duration.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participation in the study:

1. Known and previously documented homozygous genetic deficiencies (LPL, ApoC-II, ApoC-III, ApoA-V, GPIHBP1, or LMF1);
2. History of pancreatitis within the last 6 months prior to screening (Visit S1);
3. History of bariatric surgery; symptomatic gallstone disease, unless treated with cholecystectomy;
4. Abnormal liver function test at the Pre-Screening Visit or any of the Screening Visits (aspartate aminotransferase or alanine aminotransferase > 2 × the upper limit of normal [ULN], total bilirubin > 1.5 × ULN, or alkaline phosphatase > 2 × ULN based on appropriate age and gender normal values). Subjects with bilirubin > 1.5 × ULN and history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome;
5. Active liver disease (e.g., cirrhosis, alcoholic liver disease, hepatitis B [HBV], hepatitis C [HCV], autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of human immunodeficiency virus (HIV), or acquired immune deficiency virus;
6. Moderate to severe renal insufficiency defined as an estimated GFR < 60 mL/min/1.73 m2 (calculated using The Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or at any of the Screening Visits;
7. Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria), confirmed by reflexive urine protein:creatinine ratio testing;
8. Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or > 1.5 × ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to the Screening Visit;
9. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus HbA1c value ≥8.5% based on results from the Pre-Screening Visit or the Screening Visit), or any diabetic subject taking a thiazolidinedione (e.g., pioglitazone, rosiglitazone);
10. New York Heart Association Class III or IV heart failure (see Appendix C);
11. Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit (S1). Subjects with adequately treated stable angina, per Investigator assessment, may be included;
12. Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Study Day 1 prior to dosing ECG (QTcF > 450 msec for men and >470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death;
13. Uncontrolled hypertension, defined as sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg, and confirmed by repeat measurement;
14. Currently receiving cancer treatment(s) or, in the Investigator's opinion, at risk of relapse for recent cancer;
15. Inadequate washout of a PCSK9 inhibitor (8 weeks prior to the Screening Visit S1), a fibrate lipid lowering agent (6 weeks prior to the Screening Visit S1), niacin > 200 mg/day, OMG-3, bile acid sequestrants or other lipid lowering therapies (4 weeks prior to the Screening Visit S1);
16. Use of any excluded medications or supplements within 3 months prior to S1 (e.g., potent cytochrome P450 [CYP] 3A4 inhibitors, see Appendix D);
17. Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid regulating agent;
18. History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subject alcohol restrictions (see Section 5.6.3);
19. Previously treated with gemcabene (i.e., CI-1027); participation in another clinical study of an investigational agent or device concurrently or within 1 month prior to the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit; or
20. Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Gemcabene 300 mg; Participants received 300 mg Gemcabene orally, once daily for 12 weeks.	Drug: Gemcabene; Gemcabene tablets administered orally once daily, for 12 weeks.
Experimental: Gemcabene 600 mg; Participants received 600 mg Gemcabene orally, once daily for 12 weeks.	Drug: Gemcabene; Gemcabene tablets administered orally once daily, for 12 weeks.
Placebo Comparator: Placebo; Participants received matching placebo orally, once daily for 12 weeks.	Drug: Placebo; Placebo tablets administered orally once daily, for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using last observation carried forward (LOCF).	Baseline, EOS (average of week 10 and 12)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in Fasting Serum TG		Baseline, Weeks 2, 6, 10 and 12
Change From Baseline in Fasting Serum TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in TC	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in TC	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Non-HDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Non-HDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in VLDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in VLDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in HDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in HDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Apolipoprotein B	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Apolipoprotein B	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Apolipoprotein A-I	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Apolipoprotein A-I	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Apolipoprotein A-II	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Apolipoprotein A-II	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Apolipoprotein C-II	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Apolipoprotein C-II	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Apolipoprotein C-III	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Apolipoprotein C-III	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Apolipoprotein E	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Apolipoprotein E	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in LDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in LDL-C	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in LDL-TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in LDL-TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in VLDL-TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in VLDL-TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in HDL-TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in HDL-TG	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Lipoprotein Size	Percent change from baseline in Particle size for VLDL, HDL and LDL were reported.	Baseline, Week 12
Change From Baseline in Lipoprotein Size	Change from baseline in Particle size for VLDL, HDL and LDL were reported.	Baseline, Week 12
Percent Change From Baseline in Lipoprotein Particle Number	Percent change from baseline in particle number for VLDL & chylomicron, LDL and IDL were reported.	Baseline, Week 12
Change From Baseline in Lipoprotein Particle Number	Change from baseline in particle number for VLDL & chylomicron, LDL and IDL were reported.	Baseline, Week 12
Percent Change From Baseline in HDL Particle Number		Baseline, Week 12
Change From Baseline in HDL Particle Number		Baseline, Week 12
Percent Change From Baseline in High-sensitivity C-reactive Protein	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in High-sensitivity C-reactive Protein	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Fibrinogen	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Fibrinogen	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Serum Amyloid A	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Serum Amyloid A	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Adiponectin	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Week 12 and EOS (average of week 10 and 12)
Change From Baseline in Adiponectin	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Week 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Angiopoietin 4	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Week 12 and EOS (average of week 10 and 12)
Change From Baseline in Angiopoietin 4	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Week 12 and EOS (average of week 10 and 12)
Percent Change From Baseline in Interleukin-6	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Change From Baseline in Interleukin-6	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)
Percentage of Participants Achieving a TG Value < 500 mg/dL (5.65 mmol/L)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.	Weeks 10, 12 and EOS (average of week 10 and 12)

Collaborators and Investigators

• Sponsor: NeuroBo Pharmaceuticals Inc.
• Investigators: Study Director: Lee Golden, MD, NeuroBo Pharmaceuticals Inc.

Study record dates

Study Major Dates

• Study Start: December 1, 2016
• Primary Completion (Actual): January 11, 2018
• Study Completion (Actual): May 9, 2018

Study Registration Dates

• First Submitted: October 24, 2016
• First Submitted That Met QC Criteria: October 24, 2016
• First Posted (Estimate): October 25, 2016

Study Record Updates

• Last Update Posted (Actual): June 25, 2020
• Last Update Submitted That Met QC Criteria: June 3, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: Hypertriglycerides
• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Hyperlipidemias; Dyslipidemias; Hypertriglyceridemia
• Other Study ID Numbers: GEM-401